Curis (NASDAQ:CRIS) Shares Cross Above Two Hundred Day Moving Average of $10.29

Curis, Inc. (NASDAQ:CRIS) passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $10.29 and traded as high as $15.12. Curis shares last traded at $14.77, with a volume of 4,734 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright cut their price objective on Curis from $51.00 to $26.00 and set a “buy” rating on the stock in a research report on Friday, February 9th.

Curis Stock Down 1.6 %

The company has a market cap of $87.00 million, a PE ratio of -1.65 and a beta of 3.72. The business’s 50 day moving average price is $11.95 and its 200-day moving average price is $10.29.

Curis (NASDAQ:CRIS) last released its quarterly earnings results on Thursday, February 8th. The biotechnology company reported ($2.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.91) by ($0.12). The firm had revenue of $2.70 million for the quarter, compared to analysts’ expectations of $2.95 million. Curis had a negative return on equity of 169.22% and a negative net margin of 473.04%. During the same period last year, the firm earned ($2.40) EPS. Equities analysts expect that Curis, Inc. will post -5.92 earnings per share for the current year.

Hedge Funds Weigh In On Curis

A hedge fund recently bought a new stake in Curis stock. Franklin Street Advisors Inc. NC acquired a new stake in shares of Curis, Inc. (NASDAQ:CRIS) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 20,128 shares of the biotechnology company’s stock, valued at approximately $219,000. Franklin Street Advisors Inc. NC owned about 0.34% of Curis at the end of the most recent reporting period. Institutional investors own 29.97% of the company’s stock.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.